Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513326 | 0.83 | ALDH1A1 (0.44) | GPR35MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL361238 | 0.83 | ALDH1A1 (0.47) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL2625709 | 0.83 | MAPT (0.43) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL10153119 | 0.81 | ALDH1A1 (0.49) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL513295 | 0.81 | LMNA (0.50) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL20085598 | 0.80 | ALDH1A1 (0.40) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL960742 | 0.80 | ALDH1A1 (0.54) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL17142137 | 0.77 | LMNA (0.39) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3431001 | 0.77 | ALDH1A1 (0.41) | MAPTMEN1KMT2ALMNARAB9A | |
| SCHEMBL370158 | 0.76 | MAPT (0.42) | MAPTMEN1KMT2ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-22 | — | — | US | disclosed |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2018075842-A1 | CONDENSED BENZODIAZEPINE DERIVATIVES AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-9833454-B2 | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833454-B2 | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833454-B2 | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170182050-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182050-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2015153709-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2593461-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| WO-2012009309-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009309-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | GPR35 2441/4885MAPT 14/4885MEN1 2689/4885 |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | MKI67, HDGF, PCLAF | GPR35 3647/4885MAPT 3696/4885MEN1 1468/4885 |
| US-20170182050-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, BACE2 | GPR35 1210/4885MAPT 24/4885MEN1 1620/4885 |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | GPR35 3647/4885MAPT 3696/4885MEN1 1468/4885 |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | GPR35 3647/4885MAPT 3696/4885MEN1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.